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Playing Polo-Like Kinase in
NRAS-Mutant Melanoma
Hsin-Yi Chen1 and Jessie Villanueva1
NRAS-mutant melanomas are extremely aggressive and highly resistant to
currently available therapeutic modalities. Hence, new targets and therapeutic
strategies for NRAS-driven melanomas are needed. As blocking NRAS directly
has not been possible thus far, targeting downstream NRAS effectors, such as
MAPK/ERK kinase (MEK), is being evaluated as an alternative therapeutic
approach. However, blocking this pathway alone has limited efﬁcacy. In this
issue, Posch et al. report on a combination approach co-targeting polo-like
kinase 1 and MEK in NRAS-mutant melanomas. This combination triggers a dual
blockade of the cell cycle machinery, leading to apoptosis, and providing a new
strategy to treat NRAS-mutant melanoma.
Journal of Investigative Dermatology (2015) 135, 2352–2355. doi:10.1038/jid.2015.253
Mutant-NRAS in melanoma
RAS is mutated in approximately 30% of
human cancers. For example, neoplasms
of the skin, pancreas, and urinary tract
carry activating mutations in the RAS
isoforms NRAS, KRAS, and HRAS, respec-
tively (Prior et al., 2012). In melanoma,
approximately 25% of tumors harbor
NRAS mutations. Most NRAS muta-
tions affect codon 61, locking the small
G protein in the active guanosine
triphosphate-bound form and leading to
persistent RAS signaling (Ascierto et al.,
2013; Burd et al., 2014). Oncogenic
NRAS activates several signaling path-
ways, including the mitogen-activating
protein kinase (MAPK), PI3K/mTOR,
and Ral GDP dissociation stimulator
(RalGDS), resulting in aberrant cell pro-
liferation and increased tumor cell survi-
val. Attempts to inhibit oncogenic NRAS
directly have not been successful to date,
prompting a search for alternative strate-
gies to blunt NRAS signaling. Suppression
of the NRAS effector pathway MAPK
(RAF/MEK/ERK) with MEK (MAPK/ERK
kinase) inhibitors (MEKi) has been eval-
uated in clinical trials of NRAS-mutant
melanoma; however, response rates
were barely 20% and short-lived
(Ascierto et al., 2013). Immune check-
point inhibitors are only approved for
BRAF-mutant patients thus far, and their
role in treating NRAS-mutant melanoma
remains to be established. Additionally, it
has been reported recently that NRAS-
mutant melanomas are associated with
lower levels of lymphocyte inﬁltration,
suggesting a more immunosuppressive
microenvironment and possibly poor
responses to immunotherapy (Thomas
et al., 2015). Consequently, identifying
novel targets and/or co-targeting other
NRAS-speciﬁc vulnerabilities are essential
for designing effective treatments for these
types of tumors. In this issue of the Journal
of Investigative Dermatology, Posch et al.
(2015) report on suppressing a mitotic
master Ser/Thr kinase, polo-like kinase 1
(PLK1) in combination with MEK inhibi-
tion as a therapeutic strategy for NRAS-
mutant melanoma (Figure 1; Posch et al.,
2015).
Polo-like kinase: a new therapeutic target
for NRAS-mutant melanoma
PLK1 has emerged as a therapeutic
target in cancer as it regulates cell cycle
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progression and genome integrity, and it
is highly expressed in many types of
tumors. Expression of PLK1 is inversely
correlated with patients’ survival in non-
small cell lung, head and neck, and
esophageal cancer (Yim and Erikson,
2014). PLK1 has a key role in M-phase
progression; it regulates centrosomal matu-
ration, mitotic spindle assembly, chromo-
somal segregation, and cytokinesis. During
the G2/M transition, PLK1 phosphorylates
the mitotic regulator cyclin B-Cdk1 and
the phosphatase Cdc25, which activates
Cdk1, facilitating mitotic entry (Yim and
Erikson, 2014). In addition, PLK1 has a key
role in maintaining DNA integrity and
DNA damage responses (Yim and Erikson,
2014).
Preclinical studies indicate that PLK1
is, indeed, a promising therapeutic target,
especially for RAS-mutant tumors (Luo
et al., 2009; Yim and Erikson, 2014). Luo
et al. (2009) identiﬁed essential mitotic
genes, including PLK1, in a genome-
wide short hairpin RNA screen in human
KRAS-mutant cancer cells. Inhibition
of mitotic regulators such as PLK1 led
to profound G2/M arrest and caused
synthetic lethality in KRAS-mutant tumor
cells. Likewise, genetic or pharmacologi-
cal inhibition of PLK1 caused apoptosis
selectively in KRAS-mutated tumors (Yim
and Erikson, 2014), consistent with the
notion that RAS oncogenes create mitotic
stress (Luo et al., 2009). This suggests
that these types of tumors could be
hypersensitive to mitotic disruption.
PLK1 inhibitors (PLK1i) have been evalu-
ated in clinical trials as treatment for
advanced malignancies, including acute
myeloid leukemia and solid tumors
such as non-small cell lung, pancreatic,
prostate, ovarian, and urothelial cancer
(Gjertsen and Schoffski, 2015). Compounds
currently under clinical evaluation include
NMS-P937, GSK461364, BI2536, and
BI6727 (volasertib) (Strebhardt, 2010).
Notably, the potent and selective PLK1
inhibitor volasertib has been granted break-
through therapy designation by the Food
and Drug Administration (FDA).
Previous studies in melanoma also
support the promise of PLK1 as a thera-
peutic target. PLK1 is overexpressed
in cultured melanoma cell lines and in
patient samples (Schmit et al., 2009).
Inhibition of PLK1 by short hairpin RNA
or small molecule inhibitors induces
cell cycle arrest, mitotic catastrophe,
and apoptosis in melanoma cells
(Schmit et al., 2009). Posch et al. (2015)
targeted PLK1 and MEK simultaneously,
as a potential therapeutic strategy for
NRAS-driven melanoma. The investi-
gators demonstrated increased PLK1
expression in NRAS-mutant melanomas;
PLK1 mRNA levels were higher in NRAS-
mutant melanoma cell lines compared
with levels expressed in cells lines
harboring wild-type (WT) NRAS. Further-
more, ectopic expression of mutant
NRAS in melanocytes upregulated PLK1
mRNA and protein levels. The increased
expression of PLK1 was notably asso-
ciated with the most frequent NRAS
mutation (Q61) in melanoma (Ascierto
et al., 2013; Burd et al., 2014).
These ﬁndings prompted the investi-
gators to evaluate the value of co-
targeting PLK1 and the MAPK pathway,
Clinical Implications
● New therapies have emerged for BRAF-mutant melanoma, but NRAS-
mutant melanoma continues to have poor prognosis and limited
therapeutic options.
● PLK1 has emerged as a promising therapeutic target in cancer. Oncogenic
NRAS induces high expression of PLK1, providing the rationale to target
this kinase in melanoma.
● Several PLK1 small molecule inhibitors are undergoing clinical investiga-
tion, facilitating the translation of this approach.
● Co-inhibition of MEK and PLK1 triggers dual cell cycle blockade; this
approach can be superior to arresting tumors in a single cell cycle phase.
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Figure 1. Polo-like kinase 1 (PLK1) inhibitors synergize with MAPK/ERK kinase (MEK) inhibitors in NRAS(Q61) mutant melanoma. NRAS (Q61) mutants
activate the MAPK pathway and increase PLK1 expression (thick black arrows). PLK1 promotes centrosomal maturation, spindle assembly, chromosomal
segregation, and cytokinesis (orange arrows). Suppression of MEK (magenta) leads to cell cycle arrest in G0/G1 and apoptosis. Inhibition of PLK1 synergizes with
MEK inhibitors (MEKi). Polo-like kinase 1 inhibitor (PLK1i; volasertib; magenta) arrests cells in G2/M and traps cells that escape from G0/G1 by MEKi. PLK1i
can also cause monopolar spindles and mitotic catastrophe, leading to apoptosis. This activity may be partly mediated by p53. Faded colors indicate suppression
of MAPK pathway activity and M phase progression. Selected PLK1 inhibitors currently in clinical trials are included (pink). Arrowheads indicate stimulation.
Blunt lines indicate inhibition.
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which is often activated in melanoma
and seems to have a critical role in
NRAS-mutant melanoma. Inhibition
of PLK1 or MEK alone impacted the
expression of cell cycle regulatory
genes, triggering proliferation arrest.
Speciﬁcally, the MEK inhibitor trameti-
nib led to a G0/G1 arrest, whereas the
PLK1i volasertib (BI6727) arrested the
cells in G2/M. Notably, volasertib
synergized with trametinib triggering
a dual cell cycle arrest and increased
apoptosis in melanoma cell lines and
xenograft models. The investigators
further demonstrated that p53 depletion
or CHK inhibition abrogated the effec-
tiveness of this combination, suggesting
that the effect of PLK1 inhibitors might
be partially dependent on the CHK/
p53 axis.
Mechanistic explanations
One of the key effectors of NRAS is the
MEK/MAPK pathway. Yet, inhibition of
MEK alone often elicits inadequate and/or
incomplete responses in tumors with
NRAS mutations. Combination therapies
including MEK inhibitors have been
evaluated in NRAS-mutated melanoma.
In particular, combinations of MEK inhi-
bitors with CDK4/6 or PI3K/mTOR inhi-
bitors are being tested in preclinical
studies and in clinical trials (Kwong
et al., 2012; Posch et al., 2013). Unfortu-
nately, the efﬁcacy of these combinations
is frequently limited by toxicity. Furthe-
rmore, responses to these combina-
tions are often dependent on the status
of other concurrent genetic alterations; for
example, loss of p16/CDKN2A can
modulate the response to a MEK/CDK
combination. The study by Posch et al.
demonstrated that concurrent block-
ade of the central mitotic kinase PLK1
and the NRAS downstream effector
MEK induces apoptosis synergistically in
NRAS-mutant melanoma cells. PLK1 inhi-
bitors likely synergize with MEK inhibitors
by two mechanisms: (1) independent
dual cell cycle arrest: while MEK inhibi-
tion predominantly causes G1 arrest, PLK
inhibitors lead to a G2/M arrest; and
(2) increased induction of apoptosis. By
combining PLK1i with MEKi, cells that
might escape from arrest in one phase of
the cell cycle can be trapped in the other.
Hence, this dual cell cycle blockade
would be more effective than strategies
that arrest cells in a single phase. Because
PLK1 has key roles in DNA damage
repair and cell cycle progression, it is
possible that PLK1 inhibition might
induce apoptosis by triggering mitotic
catastrophe. Of note, missense mutations
in PLK1 are found in approximately 2.5%
of melanomas (cBioPortal). However, it
appears that the effects of PLK1 blockade
are independent of PLK1 mutation status,
although the studies that support this
effect included a limited number of
melanomas with PLK1 mutations.
Several studies have revealed a link
between PLK1 and the tumor suppressor
p53, whereby the two proteins regulate
each other in a negative fashion: while
phosphorylation of p53 by PLK1 inhibits
its activity, p53 transcriptionally represses
PLK1 expression (Yim and Erikson,
2014). Posch and colleagues propose
that the efﬁcacy of PLK1i is somewhat
dependent on p53, as silencing of p53
diminished the effect of the PLK1i and
MEK/PLK1i combination. It is important
to mention that although mutations in
p53 are infrequent in melanoma, the
tumor suppressor is often inactivated
through different mechanisms, such as
overexpression of its negative regulator
MDM2/4. In contrast to the ﬁndings
in Posch et al., previous studies have
suggested that loss of p53 is asso-
ciated with sensitivity to PLK1i (Yim and
Erikson, 2014); the underlying reason for
this tumor or drug-speciﬁc difference is
not yet well deﬁned, suggesting a need
for additional investigation. To extend
this paradigm to other NRAS-driven
cancers, the authors also explored this
combination in neuroblastoma and lung
cancer and showed encouraging results.
Overall, this study demonstrates a new
paradigm for NRAS-driven tumors, one
that warrants further scrutiny.
Perspective and future directions
Targeting the cell cycle seems to be a
promising approach in treating NRAS-
mutant melanoma. For example, a phase
1b/2 study combining LEE011, an inhi-
bitor of the G1 phase cyclin-dependent
kinases CDK4/6, with the MEK inhibitor
MEK162 (NCT01719380) showed favor-
able antitumor activity in patients with
NRAS-mutant melanoma (Sosman et al.,
2014). However, because this combina-
tion causes mainly a G1 phase cell cycle
arrest, it is plausible that a subset of tumor
cells will escape drug-induced G1 block-
ade, leading to transient responses and
eventually to tumor recurrence. Hence,
the strategy proposed by Posch et al.,
hitting the cell cycle machinery at two
different phases, may offer a more
effective approach to induce robust and
persistent cell cycle arrest.
Because trametinib and PLK1i are
undergoing clinical investigation, this
combination could be translated into
treatment strategies for patients with mela-
noma. However, additional rigorous pre-
clinical studies that take into account the
complexity, plasticity, and heterogeneity
of melanoma will be needed to support
such trials. Besides identifying a promising
combination therapy, this study also raises
questions that merit further investigation.
For example, it would be interesting to
determine whether PLK1 is a mediator of
NRAS oncogenic activity or if PLK1 miti-
gates stress created by oncogenic NRAS.
Moreover, a number of studies indicate
that PLK1 has non-mitotic functions. For
instance, it has been suggested that PLK1
can regulate PI3K and mTORC1/2
(Gjertsen and Schoffski, 2015). Are any
of the effects observed in this study medi-
ated by the RAS downstream effectors
PI3K or mTORC1/2? Because PLK1 has
been associated with melanoma meta-
stasis (Kneisel et al., 2002), would PLK1
inhibition affect metastasis? Furthermore,
when using adenosine triphosphate-
competitive PLK1 inhibitors such as
BI2536 and BI6727, the functions of
other PLK family members should be
considered, as some of these drugs can
also inhibit PLK2 and PLK3 (Strebhardt,
2010). This is important because PLK2 and
PLK3 are considered tumor suppressors.
Additionally, it has been reported that
PLK2/3 can mediate DNA and oxidative
stress responses in cancer (Strebhardt,
2010); hence, suppressing these PLK
isoforms could counteract the efﬁcacy of
PLK1 inhibition. If this were the case,
more selective PLK1 inhibitors may be
needed. It is also worth noting that the
mechanism by which NRAS regulates
PLK1 remains to be determined. In
addition, it is not yet known if other
driver genes upregulate PLK1 or if other
genetic alterations such as loss of
phosphatase and tensin homolog, which
positively regulates PLK1 (Yim and
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Erikson, 2014), affect response to PLK
inhibitors.
Other issues need further evaluation
before these ﬁndings can be translated
from bench to bedside. For example,
while PLK1 inhibitors seem to have a
manageable safety proﬁle (Gjertsen and
Schoffski, 2015), the tolerability of MEK/
PLK1i combinations remains to be
determined. In addition, identiﬁcation
of predictive biomarkers of responses to
MEK/PLK1i will be valuable. Certainly,
assessing the efﬁcacy of this combina-
tion in the context of a functional
immune system would be absolutely
necessary. Answering these questions
would provide valuable information to
advance this promising combination
and to provide rational and effective
treatment options for patients with
NRAS-mutant melanoma.
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The Broad Stroke of Hsp90 Inhibitors:
Painting over the RAF Inhibitor
Paradox
Michael J. Vido1,2 and Andrew E. Aplin1,2
The novel Hsp90 inhibitor XL888 is undergoing clinical investigation for use in
conjunction with the rapidly accelerated ﬁbrosarcoma (RAF) kinase inhibitor
vemurafenib to treat unresectable melanoma. The addition of XL888 to current
regimens may serve an additional purpose by blocking the RAF inhibitor
paradox. Such activity could reduce adverse events in patients and provide a
biomarker for the successful inhibition of Hsp90 target proteins.
Journal of Investigative Dermatology (2015) 135, 2355–2357. doi:10.1038/jid.2015.239
In this issue of Journal of Investigative
Dermatology, Phadke et al. (2015) report
results from a phase I dose-escalation
study of XL888, a novel Hsp90 inhibitor,
in combination with the rapidly
accelerated ﬁbrosarcoma (RAF) kinase
inhibitor vemurafenib in patients with
unresectable BRAF-mutant melanoma
(NCT01657591). Fifty percent of patients
with melanomas harbor an activating
valine to glutamic acid substitution
(V600E) in the serine/threonine kinase
BRAF that signals through the extracel-
lular signal-regulated kinase 1/2 (ERK1/2)
pathway. Despite initial efﬁcacy, BRAF
inhibitor monotherapy and newer BRAF/
mitogen-activated protein kinase kinase
(MEK) inhibitor combination therapy
inevitably yield to therapy resistance.
Mechanisms driving resistance include
the acquisition of NRAS mutations,
expression of BRAF splice variants,
ampliﬁcation of BRAF V600E, and the
upregulation of receptor tyrosine kinases
leading to ERK and AKT pathway activa-
tion (Hartsough et al., 2014). The use of
Hsp90 inhibitors in conjunction with
vemurafenib is being pursued to pro-
vide a broad stroke of inhibition against
these resistant pathways. Here the authors
report a second potential clinical beneﬁt,
namely, the reduction of paradoxical
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